Blackstone Clarus Gp L.p. - Net Worth and Insider Trading

Blackstone Clarus Gp L.p. Net Worth

The estimated net worth of Blackstone Clarus Gp L.p. is at least $361,317 dollars as of 2024-06-02. Blackstone Clarus Gp L.p. is the 10% Owner of Galera Therapeutics Inc and owns about 1,678,984 shares of Galera Therapeutics Inc (GRTX) stock worth over $361,317. Details can be seen in Blackstone Clarus Gp L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Blackstone Clarus Gp L.p. has not made any transactions after 2019-11-12 and currently still holds the listed stock(s).

Transaction Summary of Blackstone Clarus Gp L.p.

To

Blackstone Clarus Gp L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Blackstone Clarus Gp L.p. owns 2 companies in total, including Galera Therapeutics Inc (GRTX) , and Talaris Therapeutics Inc (TALS) .

Click here to see the complete history of Blackstone Clarus Gp L.p.’s form 4 insider trades.

Insider Ownership Summary of Blackstone Clarus Gp L.p.

Ticker Comapny Transaction Date Type of Owner
GRTX Galera Therapeutics Inc 2019-11-12 10 percent owner
TALS Talaris Therapeutics Inc 2021-05-06 10 percent owner

Blackstone Clarus Gp L.p. Latest Holdings Summary

Blackstone Clarus Gp L.p. currently owns a total of 1 stock. Blackstone Clarus Gp L.p. owns 1,678,984 shares of Galera Therapeutics Inc (GRTX) as of November 12, 2019, with a value of $361,317.

Latest Holdings of Blackstone Clarus Gp L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
GRTX Galera Therapeutics Inc 2019-11-12 1,678,984 0.22 361,317

Holding Weightings of Blackstone Clarus Gp L.p.


Blackstone Clarus Gp L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Blackstone Clarus Gp L.p. has made a total of 1 transactions in Galera Therapeutics Inc (GRTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Galera Therapeutics Inc is the acquisition of 250,000 shares on November 12, 2019, which cost Blackstone Clarus Gp L.p. around $3 Million.

Insider Trading History of Blackstone Clarus Gp L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Blackstone Clarus Gp L.p. Trading Performance

GuruFocus tracks the stock performance after each of Blackstone Clarus Gp L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Blackstone Clarus Gp L.p. is 6.05%. GuruFocus also compares Blackstone Clarus Gp L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Blackstone Clarus Gp L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Blackstone Clarus Gp L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Blackstone Clarus Gp L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -30.04 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -32.52 LIMIT LIMIT LIMIT LIMIT LIMIT

Blackstone Clarus Gp L.p. Ownership Network

Ownership Network List of Blackstone Clarus Gp L.p.

No Data

Ownership Network Relation of Blackstone Clarus Gp L.p.

Insider Network Chart

Blackstone Clarus Gp L.p. Owned Company Details

What does Galera Therapeutics Inc do?

Who are the key executives at Galera Therapeutics Inc?

Blackstone Clarus Gp L.p. is the 10 percent owner of Galera Therapeutics Inc. Other key executives at Galera Therapeutics Inc include Chief Commercial Officer Mark Bachleda , Chief Financial Officer Chris Degnan , and director & President and CEO Mel Sorensen .

Galera Therapeutics Inc (GRTX) Insider Trades Summary

Over the past 18 months, Blackstone Clarus Gp L.p. made no insider transaction in Galera Therapeutics Inc (GRTX). Other recent insider transactions involving Galera Therapeutics Inc (GRTX) include a net purchase of 3,712,809 shares made by , a net purchase of 100,000 shares made by Mel Sorensen , and a net purchase of 11,000 shares made by Mark Bachleda .

In summary, during the past 3 months, insiders sold 0 shares of Galera Therapeutics Inc (GRTX) in total and bought 2,780,407 shares, with a net purchase of 2,780,407 shares. During the past 18 months, 0 shares of Galera Therapeutics Inc (GRTX) were sold and 3,833,809 shares were bought by its insiders, resulting in a net purchase of 3,833,809 shares.

Galera Therapeutics Inc (GRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Galera Therapeutics Inc Insider Transactions

No Available Data

Blackstone Clarus Gp L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Blackstone Clarus Gp L.p.. You might contact Blackstone Clarus Gp L.p. via mailing address: C/o The Blackstone Group Inc., 345 Park Avenue, New York Ny 10154.

Discussions on Blackstone Clarus Gp L.p.

No discussions yet.